Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

The study is looking for adults aged 18 or older with advanced melanoma that is not located in the eye. You must have already received some specific previous treatments for your melanoma, including a type of therapy called anti-PD1. To join, your body's immune system needs to have a specific marker called HLA-A*02:01. The doctors will check this with a simple blood test.

There are also some requirements about your general health. You should be well enough to carry out most daily activities, and your cancer must have parts that can be measured or seen by doctors. You'll also need to provide a sample of your tumor tissue, either from one you've had taken before, or a small new biopsy.

However, some people won't be able to join. For example, if you are pregnant or breastfeeding, or if you have another type of cancer, or if your melanoma is in your eye. You also can't participate if you have severe allergies to certain medications or have an active autoimmune disease that requires specific treatments. People with untreated or severe brain metastases or mental health conditions that might affect involvement in the study will also not be eligible.

If you decide to take part in this study, you might receive tebentafusp on its own, tebentafusp with pembrolizumab, or participate in the "investigator's choice" arm, which means you'll receive a treatment chosen by your doctor based on what's currently available for your condition. This could include other clinical trials, standard care, or care focused on your comfort and quality of life.

You will have regular appointments at the hospital for treatments and check-ups. These visits will involve blood tests, physical exams, and scans (like CT scans) to see how the treatment is affecting your cancer. Some visits might include collecting extra samples for research, such as tissue biopsies. The doctor and study team will explain exactly what this means for you, including how often you'll need to visit and for how long. The study will continue as long as the treatment is helping, or until side effects make it necessary to stop, or if you decide you no longer wish to participate.